Avacta Life Sciences Limited
  • About
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Therapeutics Page 3
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Therapeutics

06 Sep 2021

Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division

Investors | Therapeutics
02 Sep 2021

Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division

Investors | Therapeutics
11 Aug 2021

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial

Investors | Therapeutics
18 Feb 2021

Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA

Investors | Therapeutics
01 Feb 2021

AffyXell $7.3 Million Series A Financing

Investors | Therapeutics
07 Jan 2021

License Agreement with POINT Biopharma Inc

Investors | Therapeutics
23 Dec 2020

Submission of Clinical Trial Application for AVA6000 Pro-doxorubixin

Investors | Therapeutics
27 Oct 2020

ShareBuyers Interview with Alastair Smith

Diagnostics | Investors | Therapeutics
18 Aug 2020

Avacta and LG Chem Life Sciences Expand Partnership

Investors | Therapeutics
11 Aug 2020

Avacta Appoints Therapeutics Chief Development Officer

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok